Related Articles
Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck
Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN
Small molecules in combination with conventional chemotherapeutic drugs: Light at the end of the tunnel?
PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells
Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation